timothy sykes logo
Hims & Hers Health Stock Dips: Buying Opportunity? Thumbnail
G Google News

Hims & Hers Health Stock Dips: Buying Opportunity?

TIM SYKES•UPDATED JUN. 15, 2026, 6:10 PM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

Hims & Hers Health Inc.’s stocks have been trading down by -2.19 percent due to market reactions surrounding their latest earnings report.

Latest Developments

  • The latest from Citi shows a price target cut for Hims & Hers Health, down to $25 from $27, maintaining a sell rating owing to a predicted slowdown in core revenue and doubts about the company’s GLP-1 strategy.
  • Queries arise on the FDA’s warnings about compounded topical finasteride, possibly swaying customers to safer alternatives, impacting Hims & Hers’ medical catalog.
  • Morgan Stanley hints a Q1 victory for Hims & Hers but warns about potentially shaky Q2 revenues, prompting some to cash in after recent gains from their partnership with Novo Nordisk.
  • Andrew Dudum, a key insider at Hims & Hers, sold shares valued at more than $3M on Apr 28, 2025, stirring concerns about insider confidence.
  • BofA notes a slowdown in Hims & Hers’ sales growth last month, notably for their GLP-1 sales, suggesting a possible dip in momentum.

Candlestick Chart

Live Update At 09:18:18 EST: On Friday, May 23, 2025 Hims & Hers Health Inc. stock [NYSE: HIMS] is trending down by -2.19%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Earnings and Financial Health

As millionaire penny stock trader and teacher Tim Sykes says, “There is always another play around the corner; don’t chase just because you feel FOMO.” Understanding this, it’s essential for traders to recognize that not every opportunity must be seized impulsively. The market is full of potential trades, and patience often results in better decisions. So, maintaining a disciplined and informed approach is crucial to success in the fast-paced world of stock trading.

Hims & Hers Health Inc is currently navigating a complex market scenario. Their Q1 reports showed a revenue stream of approximately $1.5 billion which paints an optimistic side. But the narrative shifts when considering profitability ratios, since even with a strong gross margin of 77%, other metrics spell caution. For instance, there’s a visible gap in profitability margins, marked by a slight negative pre-tax profit margin, reflecting potential volatility.

Headline figures such as the EBITDA at nearly $68 million point towards operational efficiency, albeit the net income places the spotlight on the company’s need to tighten its reins. Amidst fluctuation in revenues and overall mixed financial numbers, these statements whisper a story of vibrant growth on a backdrop of financial missteps.

More Breaking News

From a valuation angle, the sky-high P/E ratio over 85 also shines a light on expectations orbiting beyond Earth, suggesting possible investor optimism despite logical caution. This ties into their cash flow scenario, which albeit positive, shows net changes that aren’t as robust as their capital ought to exhibit at a glance.

Reaction to Recent News

Possibilities stream from the latest reviews of Hims & Hers Health — from industry analysts projecting cautious optimism, to underlying trepidation illustrated in key downgrades and lowered price targets. Even though a successful initial quarterly stretch has been acknowledged, investors wear an uneasy cloak with potential challenges reflected in their stock price’s see-saw.

Morgan Stanley and Citi have painted divergent scenes. While one sees improvement, the other hesitates. Apparent slowdowns in crucial revenue lines tug at Hims & Hers Health’s financial trajectory. It’s like seeing a vivid sunset fade to twilight — colors persist but shadows encroach.

Additionally, the nuanced FDA advisory could reshuffle customer loyalties, swaying them towards other offerings as they move to shield themselves from uncertainty. Nonetheless, these ripples in the health sector foreshadow cautious navigation, which only experienced sailors — or perhaps analyst guides, could predict.

Conclusion and Outlook

As the Hims & Hers Health unfolds in this financial theater, the company’s prowess and resilience are being evaluated against a backdrop of skepticism and press sentiment. Analyst cues ring a mixed chorus, with Morgan Stanley prompting cautious celebration while Citi echoes prudent preparedness against a dimming panorama.

Potential traders and stakeholders should brace, not merely for the market fluctuations but the depth of story intrinsic to Hims & Hers’ financial journey. While the hints of opportunity loom in their current stock dip, they call for keen scrutiny of overarching signals. As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.”

Every tick of their stock price resonates with variables, scenarios, and shifts in regulatory winds — traits that merit a trader’s curiosity and patience.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”